10-Q: Veru Inc. Reports Q1 2024 Results, Focuses on Enobosarm Development

Veru Inc. reported a net loss of $8.3 million for the quarter ended December 31, 2023, while advancing its enobosarm program and managing its existing FC2 business.

Summary

• Veru Inc. reported a net loss of $8.3 million for the quarter ended December 31, 2023, compared to a net loss of $38.7 million for the same period in 2022.
• Net revenues for the quarter were $2.1 million, a decrease of 15% compared to the prior year, primarily from sales of FC2.
• The company's gross profit increased to $1.2 million, with a gross profit margin of 54%, up from 28% in the prior year, due to a shift in sales mix towards the higher-margin U.S. prescription channel.
• Research and development expenses decreased significantly to $1.7 million, down from $20.6 million in the prior year, due to a strategic refocusing of development efforts.
• Selling, general, and administrative expenses also decreased to $8.3 million from $17.5 million in the prior year, primarily due to reduced commercialization costs.
• The company recorded a gain of $0.9 million from the sale of ENTADFI assets.
• Veru completed a public offering of common stock, raising net proceeds of approximately $35.2 million.
• The company's cash and cash equivalents increased to $40.6 million at the end of the quarter, up from $9.6 million at the end of the previous quarter.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in reducing losses and raising capital, it faces significant challenges, including declining revenue, material weaknesses in internal controls, and risks related to its financial position and development programs. The sentiment is neutral to slightly negative.

Positives

• The company significantly reduced its net loss compared to the same quarter last year.
• Gross profit margin improved due to a change in sales mix.
• Operating expenses were significantly reduced due to a strategic refocus.
• The company successfully raised capital through a public offering.
• The company received FDA clearance to initiate a Phase 2b clinical trial for enobosarm.
• The company's cash position improved significantly.

Negatives

• Net revenues decreased by 15% compared to the same quarter last year.
• The company is still experiencing losses.
• The company is not in compliance with a provision of the Jefferies Sales Agreement which would prevent it from making additional sales under the Jefferies Sales Agreement unless such non-compliance is waived.
• The company is currently ineligible to file new registration statements on Form S-3 until no earlier than March 1, 2025.
• There is a substantial risk that BWV will not make any payment on the outstanding notes receivable when due.

Risks

• The company's future capital requirements are uncertain and depend on various factors.
• The company may need to raise additional capital through debt or equity financing.
• The company's failure to timely file reports with the SEC may impair its ability to raise capital.
• There is a risk that the company may not receive additional payments from Onconetix, Inc. (formerly Blue Water Vaccines Inc.) in connection with the sale of ENTADFI assets.
• The company is reliant on a single supplier for its principal raw material for FC2.
• The company is subject to risks related to the development of its product portfolio, including clinical trials and regulatory approvals.
• The company is subject to risks related to intellectual property, competition, and compliance and regulatory matters.
• The company is subject to risks inherent in doing business on an international level.
• The company is subject to risks related to the restatement of its financial statements.
• The company is subject to government contracting risks.
• The company is subject to risks related to the Shareholder Litigation.

Future Outlook

The company plans to continue developing enobosarm for obesity and breast cancer, and is seeking external funding for sabizabulin. The company expects revenue from the U.S. prescription channel to grow and is working to secure new commercial distribution strategies. The company is also working to resume distribution of FC2 in the global public sector.

Management Comments

• Management believes its current cash position and cash expected to be generated from sales of FC2 will be adequate to fund planned operations of the Company for the next 12 months.
• Management intends to be opportunistic when pursuing equity or debt financing.
• Management believes that the unaudited condensed consolidated financial statements included in this Form 10-Q as of and for the three-month period ended December 31, 2023 fairly present, in all material respects, our financial condition, results of operations, and cash flows for the period presented in conformity with U.S. GAAP.

Industry Context

The company is operating in the biopharmaceutical industry, which is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company is also operating in the sexual health market, which is subject to competition from other contraceptive products. The company's focus on enobosarm for obesity and breast cancer aligns with the growing demand for new treatments in these areas. The company's FC2 product is positioned in the global public health sector, which is subject to government funding and procurement processes.

Comparison to Industry Standards

• Veru's reduction in R&D spending is a common strategy for companies that are prioritizing specific programs and seeking to conserve cash, similar to other small-cap biotech firms.
• The company's focus on enobosarm for sarcopenic obesity is a novel approach, as most companies are focused on weight loss alone, not muscle preservation, which is a key differentiator.
• The company's reliance on a single supplier for FC2 raw materials is a risk, which is not uncommon for smaller companies, but larger companies often have diversified supply chains.
• The company's telehealth strategy for FC2 is similar to other companies in the sexual health space, but the company's own portal gives it more control over distribution and sales.
• The company's public offering is a common way for biotech companies to raise capital, but the company's ineligibility to file new registration statements on Form S-3 is a significant disadvantage compared to other companies.
• The company's financial results are mixed, with improved profitability but decreased revenue, which is not uncommon for companies in the early stages of commercialization.

Legal Proceedings

• The company is involved in several shareholder lawsuits, including the Ewing Lawsuit, Maglia Lawsuit, Franchi Lawsuit, Renbarger Lawsuit, and Alshourbagy Lawsuit.
• The company is unable to estimate potential losses, if any, related to the Shareholder Litigation.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, stock price, and potential dilution from equity offerings.
• Employees are impacted by the company's financial stability and strategic direction.
• Customers are impacted by the availability and pricing of the company's products.
• Suppliers are impacted by the company's ability to pay for goods and services.
• Creditors are impacted by the company's ability to repay its debts.

Next Steps

• The company plans to initiate a Phase 2b clinical trial for enobosarm in April 2024.
• The company expects topline clinical results from the Phase 2b trial in the end of the fourth calendar quarter of 2024.
• The company expects results from the Phase 2b open label extension clinical study in the second quarter of calendar year 2025.
• The company will continue to evaluate the collectability of the notes receivable for future installments of the purchase price from BWV.
• The company will continue to implement its remediation plan for the current material weaknesses in internal control over financial reporting.

Key Dates

Keywords

enobosarm, FC2, sarcopenic obesity, GLP-1 RA, breast cancer, sabizabulin, ARDS, telehealth, clinical trial, FDA, public offering, financial results